Key Highlights

  • Imunon stock was up USD 0.08, or 8.89%, to USD 0.98 in pre-market trading on November 4, 2026.
  • Second-quarter 2026 net loss was USD 2.8 million, or USD 0.54 per share, versus USD 2.7 million a year earlier.
  • Cash and equivalents were USD 6.9 million at June 30, 2026, down from USD 8.8 million at December 31, 2025.
  • A June 4, 2026 financing was announced with up to USD 10 million in expected gross proceeds for the Phase 3 trial.
  • The company expects OVATION 3 enrollment to be completed by the first half of 2029.

What Moved Imunon Before the Open (up USD 0.0800, 8.89%)

Imunon (NASDAQ:IMNN) shares were up USD 0.08, or 8.89%, to USD 0.98 in pre-market trading on November 4, 2026. The Tuesday, November 3 close was therefore about USD 0.90 (calculated).

No company press release, regulatory filing or trial readout dated November 3 or November 4, 2026 was identified in the sources reviewed. The company has not confirmed a date for its third-quarter report, so the gain appears to be trading momentum in a low-priced clinical-stage biotech, not a response to a specific disclosure.

The Clinical and Financing Story in Detail

Imunon develops DNA-based immunotherapies, and its lead candidate IMNN-001 is being tested in the Phase 3 OVATION 3 trial in newly diagnosed advanced ovarian cancer. According to a company press release dated June 4, 2026, the Phase 2 OVATION 2 study showed median overall survival rising from 11.1 months to 14.7 months with IMNN-001 added to standard chemotherapy.

The same release outlined a financing with expected aggregate gross proceeds of up to USD 10 million. It included 250 shares of non-redeemable, non-convertible preferred stock for USD 2.5 million and secured promissory notes totalling USD 7.72 million, with rates of 8% and 5% and maturities 18 months after issuance. The company said there were no warrants.

Recent Results and Updates

In its second-quarter 2026 results dated August 11, 2026, Imunon reported a net loss of USD 2.8 million, or USD 0.54 per share, against USD 2.7 million, or USD 2.15 per share, in the same quarter of 2025. For the first half, the net loss was USD 7.1 million, or USD 1.38 per share.

Research and development expense was USD 1.5 million, up from USD 1.2 million, while general and administrative expense fell to USD 1.3 million from USD 1.5 million. Operating cash use for the first half was USD 7.0 million, up from USD 5.8 million.

Management said OVATION 3 enrollment is running ahead of its forecast and expects enrollment to complete in the first half of 2029.

Balance Sheet and Risks

Cash and equivalents of USD 6.9 million at June 30, 2026 compare with the USD 7.0 million used in operations during the first six months, which suggests a short funding horizon without further Capital (calculated reading, not a company statement). The Balance Sheet also showed USD 5.0 million in restricted cash. The company did not give a cash runway estimate in that release.

At under USD 5, Imunon is a penny stock, so shares can move sharply on thin liquidity, and additional financing could dilute existing holders. Forward-looking language in the release also referred to a planned stock split, for which no ratio or timing was provided, and the screen price should be read with that in mind.

What to Watch Next

Key items are the third-quarter 2026 report and its cash figure, any new financing or listing compliance notice, the planned Stock Split details, and enrollment updates from OVATION 3.